--- title: "BIOTRICITY INC. (BTCY) stock: news and investor profile" url: "https://aibio.space/companies/biotricity/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "BIOTRICITY INC. (OTC: BTCY), United States. Listing facts, related biotech companies and news on aibio.space." --- BTCY BIOTRICITY INC. OTC · United States # BIOTRICITY INC. (BTCY) news BIOTRICITY INC. is a public biotech or pharmaceutical company listed on OTC under the ticker BTCY, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest BIOTRICITY INC. news We have not published a story on BIOTRICITY INC. yet. When there is news, it will appear here. ## BIOTRICITY INC. at a glance - **Ticker**: BTCY - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $466,503 ### Related companies - [Anteris Technologies Global](https://aibio.space/companies/anteris-technologies-global/) NASDAQ: AVR - [Yubo International Biotech](https://aibio.space/companies/yubo-international-biotech/) OTC: YBGJ - [IMMUCELL CORP /DE/](https://aibio.space/companies/immucell-de/) NASDAQ: ICCC - [ENvue Medical](https://aibio.space/companies/envue-medical/) OTC: FEED - [Bioventus](https://aibio.space/companies/bioventus/) NASDAQ: BVS - [NEOGEN CORP](https://aibio.space/companies/neogen/) NASDAQ: NEOG - [20/20 Biolabs](https://aibio.space/companies/20-20-biolabs/) NASDAQ: AIDX - [ALPHA PRO TECH LTD](https://aibio.space/companies/alpha-pro-tech/) NYSE: APT ### Also on OTC - [Manhattan Scientifics](https://aibio.space/companies/manhattan-scientifics/) MHTX - [Adaptimmune Therapeutics](https://aibio.space/companies/adaptimmune-therapeutics/) ADAPY - [Wuhan General Group (China)](https://aibio.space/companies/wuhan-general-china/) WUHN - [ADM TRONICS UNLIMITED, INC.](https://aibio.space/companies/adm-tronics-unlimited/) ADMT - [Trafalgar International](https://aibio.space/companies/trafalgar-international/) TRFA - [Vicarious Surgical](https://aibio.space/companies/vicarious-surgical/) RBOT ## What BIOTRICITY INC. does Biotricity Inc. is a medical technology company focused on biometric data monitoring, offering remote monitoring solutions to the medical, healthcare and consumer markets. It first focused on mobile cardiac outpatient monitoring with its Bioflux device and software, which has FDA clearance. Its flagship technology is the Biocore Pro, the cellular version of its three-lead Biocore device for ECG and arrhythmia monitoring, which is intended for lower risk patients. The company also offers Bioheart, a direct-to-consumer heart monitor. It says it has expanded its sales efforts to 35 states and intends to compete more broadly in the US market using an insourcing model, in which physicians use its technology and the company earns utilization-based technology service fees. The company has obtained regulatory approvals in several jurisdictions outside the US. It plans to expand into remote patient monitoring, chronic care management and implantable device management, with a goal of becoming an all-in-one cardiac diagnostic and disease management solution. Target customers include hospitals, clinics, physicians' offices and independent diagnostic testing facilities. | Product or program | What it is | Stage | |---|---|---| | Bioflux | Mobile cardiac outpatient monitoring device and software | FDA cleared | | Biocore Pro | Cellular three-lead ECG and arrhythmia monitoring device, flagship technology | launched | | Biocore | Three-lead connected Holter monitoring patch for lower risk patients | FDA cleared | | Bioheart | Direct-to-consumer heart monitor | launched | Summarised from the company's [10-K filed Jul 14, 2026](https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/form10-k.htm). ## BIOTRICITY INC. annual financials | Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 | |---|---|---| | Research and development | [$2.8 million](https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/) | [$2.2 million](https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/) | | Net income (loss) | [-$2.4 million](https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/) | [-$8.4 million](https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/) | | Cash from operations | [-$718,955](https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/) | [-$2.4 million](https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/) | | Cash and equivalents | [$149,789](https://www.sec.gov/Archives/edgar/data/1630113/000149315226039209/) | [$365,145](https://www.sec.gov/Archives/edgar/data/1630113/000149315226033207/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $466,503. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about BIOTRICITY INC. What is the ticker symbol of BIOTRICITY INC.? BIOTRICITY INC. trades under the ticker BTCY on OTC. Where is BIOTRICITY INC. listed? BIOTRICITY INC. is listed on OTC. Which country or territory is BIOTRICITY INC. listed under? Our directory records BIOTRICITY INC. under United States. Does aibio.space cover BIOTRICITY INC.? aibio.space lists BIOTRICITY INC. among 2,820 public biotech companies and publishes its news here as stories appear. What does BIOTRICITY INC. develop? Biotricity Inc. is a medical technology company focused on biometric data monitoring, offering remote monitoring solutions to the medical, healthcare and consumer markets. It first focused on mobile cardiac outpatient monitoring with its Bioflux device and software, which has FDA clearance. What is Bioflux from BIOTRICITY INC.? Bioflux: Mobile cardiac outpatient monitoring device and software Stage: FDA cleared. What is Biocore Pro from BIOTRICITY INC.? Biocore Pro: Cellular three-lead ECG and arrhythmia monitoring device, flagship technology Stage: launched. Is BIOTRICITY INC. profitable? BIOTRICITY INC. reported a net loss of $2.4 million for the fiscal year ended Mar 31, 2026, and used $718,955 of cash in operations, per its annual report to the SEC. How much does BIOTRICITY INC. spend on research and development? $2.8 million in the fiscal year ended Mar 31, 2026, per its annual report. How much cash does BIOTRICITY INC. have? $466,503 in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: BIOTRICITY INC. Members talk about BIOTRICITY INC. (BTCY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at BIOTRICITY INC., newest first. Each line links the filing it comes from. 1. 2026-08-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1630113/000149315226038710/formnt10-q.htm) 2. 2026-06-29 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1630113/000149315226030382/formnt10-k.htm) 3. 2026-05-01 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1630113/000149315226020939/form8-k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:BTCY on TradingView](https://www.tradingview.com/symbols/OTC-BTCY/). ## Listing details BIOTRICITY INC. is a public biotech or pharmaceutical company listed on OTC under the ticker BTCY, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: BIOTRICITY INC. - **Ticker**: BTCY - **Listing**: OTC - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/biotricity/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BIOTRICITY INC. (BTCY) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/biotricity/